MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect MeiraGTx to post earnings of ($0.60) per share and revenue of $3.8710 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

MeiraGTx Stock Up 5.3%

Shares of MGTX opened at $7.76 on Wednesday. The company has a market capitalization of $624.60 million, a P/E ratio of -3.68 and a beta of 1.37. MeiraGTx has a one year low of $4.55 and a one year high of $9.73. The business’s 50 day simple moving average is $7.59 and its 200-day simple moving average is $7.94. The company has a debt-to-equity ratio of 26.29, a current ratio of 0.22 and a quick ratio of 0.22.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. HC Wainwright began coverage on MeiraGTx in a research report on Monday, November 24th. They issued a “buy” rating and a $20.00 price objective for the company. Piper Sandler increased their target price on MeiraGTx from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Royal Bank Of Canada raised their target price on MeiraGTx from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MeiraGTx in a research report on Thursday, January 22nd. Finally, Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of MeiraGTx in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $26.00.

Hedge Funds Weigh In On MeiraGTx

Several institutional investors have recently modified their holdings of MGTX. AQR Capital Management LLC acquired a new stake in shares of MeiraGTx in the 1st quarter valued at approximately $557,000. Rhumbline Advisers grew its holdings in MeiraGTx by 9.4% during the second quarter. Rhumbline Advisers now owns 63,715 shares of the company’s stock valued at $415,000 after purchasing an additional 5,488 shares during the period. Brown Advisory Inc. bought a new stake in MeiraGTx in the second quarter valued at approximately $326,000. Qube Research & Technologies Ltd bought a new stake in MeiraGTx in the second quarter valued at approximately $530,000. Finally, Quantinno Capital Management LP acquired a new stake in MeiraGTx in the second quarter worth $319,000. 67.48% of the stock is currently owned by institutional investors and hedge funds.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.